Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, whether the Joint Committee on Vaccination and Immunisation's assessment of the cost-effectiveness of HPV vaccination for boys includes the (a) social care, (b) social security and (c) other costs of HPV-related diseases that are not borne directly by the NHS; and if he will make a statement.

The Joint Committee on Vaccination and Immunisation (JCVI) follows standard guidelines from the National Institute for Health and Care Excellence on mathematical modelling and cost-effectiveness. This means that the JCVI takes into account the costs and benefits of a programme from a health perspective to ensure that the best possible health outcomes are delivered from the health, and where relevant, social care budgets.

The JCVI expects to receive a report from Public Health England in early 2017 on the impact and cost effectiveness of extending the human papillomavirus vaccination to adolescent boys. As part of its considerations the JCVI will review whether all appropriate costs and benefits have been taken into account.